Prioritizing the worries of AML patients: Quantifying patient experience using best-worst scaling.
Daniel R RichardsonAllison H OakesNorah L CrossnohereGary RathsmillCrystal ReinhartBernadette O'DonoghueJohn F P BridgesPublished in: Psycho-oncology (2021)
This large convenience sample demonstrates that AML patients have two principal worries: dying from their disease and suffering long-term side effects from treatment. To better foster patient-centered care, therapeutic decision-making and drug development should reflect the importance of both potential outcomes. Further work should explore interventions to address these worries.